1. Home
  2. RITM vs NUVL Comparison

RITM vs NUVL Comparison

Compare RITM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rithm Capital Corp.

RITM

Rithm Capital Corp.

HOLD

Current Price

$11.96

Market Cap

6.5B

Sector

Real Estate

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$111.42

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RITM
NUVL
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
7.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RITM
NUVL
Price
$11.96
$111.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
15
Target Price
$14.22
$135.00
AVG Volume (30 Days)
8.0M
509.2K
Earning Date
01-30-2026
02-26-2026
Dividend Yield
8.51%
N/A
EPS Growth
46.96
N/A
EPS
1.45
N/A
Revenue
$3,961,432,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.71
N/A
P/E Ratio
$8.10
N/A
Revenue Growth
32.03
N/A
52 Week Low
$9.13
$55.54
52 Week High
$12.74
$112.88

Technical Indicators

Market Signals
Indicator
RITM
NUVL
Relative Strength Index (RSI) 67.33 61.08
Support Level $11.05 $101.25
Resistance Level $11.81 $108.65
Average True Range (ATR) 0.25 5.53
MACD 0.07 0.90
Stochastic Oscillator 92.15 91.35

Price Performance

Historical Comparison
RITM
NUVL

About RITM Rithm Capital Corp.

Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: